Former FDA commissioner Scott Gottlieb came out against president-elect Trump’s choice of Robert F. Kennedy Jr. to lead the ...

Johnson & Johnson has filed for two new pediatric indications as it looks to position its blockbuster immunotherapy Tremfya ...

The FDA is defending its increased use of non-binding guidance documents rather than legally-enforceable rulemakings, arguing ...

Sanofi has made its single largest investment in China to date by pouring roughly €1 billion ($1.05 billion) into a new ...

Biocon Biologics scored an FDA approval for its Stelara biosimilar, marketed as Yesintek, the company announced Monday.

Merus reported updated Phase 2 trial results for petosemtamab in head and neck cancer, showing 40.4% overall response rate ...

Novocure announced Monday morning that its electrical field wearable device combined with chemotherapy passed a late-stage ...

Olema Oncology and Novartis partner for Phase 3 trial combining palazestrant with Kisqali for breast cancer treatment. Olema ...

Novartis is returning to Huntington's disease with a $1 billion upfront bet, plus another $1.9 billion in biobucks, for ...

Agenus Bio is launching a CDMO arm using facilities in Berkeley and Emeryville, CA, while cutting spending to $100M by 2025.

Apogee Therapeutics plans to challenge Sanofi and Regeneron's Dupixent with its lead drug APG777, an IL-13 targeting ...

Acadia Pharmaceuticals will pay Saniona $28 million upfront and up to $582 million in milestone payments for SAN711, an ...